Publications by authors named "Jonathan Dabora"

Claim this Profile
H
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States.
Sikander Ailawadhi, Mu Cheng, Maral DerSarkissian, Jonathan Dabora, Melanie Young

J Manag Care Spec Pharm· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Karthik Ramasamy, Nizar J Bahlis, Shaji K Kumar, Arun Kumar, Holly Cranmer, Jonathan Dabora

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Maral DerSarkissian, Holly Cranmer, Jonathan Dabora, Iryna Bocharova, Dasha Cherepanov

Hematology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Larysa Sanchez, Ajai Chari, Mu Cheng, Dasha Cherepanov, Maral DerSarkissian, Jonathan Dabora

J Manag Care Spec Pharm· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis